Literature DB >> 16231364

Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.

Giovanni Musso1, Roberto Gambino, Marilena Durazzo, Giampaolo Biroli, Monica Carello, Emanuela Fagà, Giovanni Pacini, Franco De Michieli, Laura Rabbione, Alberto Premoli, Maurizio Cassader, Gianfranco Pagano.   

Abstract

Circulating levels of four adipokines (adiponectin, TNF-alpha, leptin, and resistin) and the postprandial lipid and adiponectin responses to an oral fat load were assessed in 25 non-obese, non-diabetic patients with biopsy-proven nonalcoholic steatohepatitis (NASH) and correlated with metabolic indices and liver histology. Circulating adiponectin was lower in NASH compared with controls (5,476 +/- 344 vs. 11,548 +/- 836 ng/mL; P = .00001) and on multiple regression analysis correlated negatively with liver steatosis, necroinflammation (OR = 5.0; P = .009), and fibrosis (OR = 8.0; P = .003). The magnitude of postprandial lipemia was significantly higher in NASH than in controls and was related to fasting adiponectin (beta = -0.78; P = .00003). Controls showed a significant increase in serum adiponectin in response to the fat load, whereas patients with NASH showed a slight decrease. Postprandial free fatty acids response correlated inversely with adiponectin response in both groups and independently predicted the severity of liver steatosis in NASH (beta = 0.51; P = .031). In conclusion, hypoadiponectinemia is present before overt diabetes and obesity appear and correlates with the severity of liver histology in NASH. Impaired postprandial lipid metabolism may be an additional mechanism linking hypoadiponectinemia and NASH and posing a higher cardiovascular risk to these subjects. The mechanism(s) underlying these differences are unknown, but the type of dietary fat seems to play a role. These findings may have important pathogenetic and therapeutic implications in both liver and metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231364     DOI: 10.1002/hep.20896

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  62 in total

1.  Assessment of endothelial function in patients with nonalcoholic fatty liver disease.

Authors:  Yasar Colak; Ebubekir Senates; Atakan Yesil; Yusuf Yilmaz; Oguzhan Ozturk; Levent Doganay; Ender Coskunpinar; Ozlem Timirci Kahraman; Banu Mesci; Celal Ulasoglu; Ilyas Tuncer
Journal:  Endocrine       Date:  2012-06-03       Impact factor: 3.633

Review 2.  Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Authors:  Steven D Lidofsky
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

3.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 4.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

5.  A human-type nonalcoholic steatohepatitis model with advanced fibrosis in rabbits.

Authors:  Tomohiro Ogawa; Hideki Fujii; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

6.  A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

Authors:  Gianluca Svegliati-Baroni; Cinzia Candelaresi; Stefania Saccomanno; Gianna Ferretti; Tiziana Bachetti; Marco Marzioni; Samuele De Minicis; Liliana Nobili; Renata Salzano; Alessia Omenetti; Deborah Pacetti; Soeren Sigmund; Antonio Benedetti; Alessandro Casini
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

7.  Lean NAFLD: An Underrecognized Outlier.

Authors:  Julia Wattacheril; Arun J Sanyal
Journal:  Curr Hepatol Rep       Date:  2016-04-14

8.  Variations of serum levels of adiponectin and resistin in chronic viral hepatitis.

Authors:  M Durazzo; P Belci; G Niro; A Collo; E Grisoglio; V Ambrogio; M Spandre; R Fontana; R Gambino; M Cassader; S Bo
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

9.  Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.

Authors:  Marianna Argentou; Dina G Tiniakos; Menelaos Karanikolas; Maria Melachrinou; Maria G Makri; Christos Kittas; Fotis Kalfarentzos
Journal:  Obes Surg       Date:  2009-07-15       Impact factor: 4.129

Review 10.  A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease.

Authors:  P Riley; J O'Donohue; M Crook
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.